Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
24.11
+0.25 (1.05%)
At close: Apr 14, 2026, 4:00 PM EDT
24.12
+0.01 (0.05%)
After-hours: Apr 14, 2026, 4:19 PM EDT
Elanco Animal Health Employees
As of December 31, 2025, Elanco Animal Health had 9,900 total employees, including 9,400 full-time and 500 part-time employees. The number of employees increased by 450 or 4.76% compared to the previous year.
Employees
9,900
Change (1Y)
450
Growth (1Y)
4.76%
Revenue / Employee
$476,263
Profits / Employee
-$23,434
Market Cap
12.04B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 9,900 | 450 | 4.76% | 9,400 | 500 |
| Dec 31, 2024 | 9,450 | -350 | -3.57% | 9,000 | 450 |
| Dec 31, 2023 | 9,800 | 60 | 0.62% | 9,300 | 500 |
| Dec 31, 2022 | 9,740 | 740 | 8.22% | 9,000 | 740 |
| Dec 31, 2021 | 9,000 | -1,200 | -11.76% | 9,000 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Alkermes | 2,050 |
| Neurocrine Biosciences | 2,000 |
| United Therapeutics | 1,400 |
ELAN News
- 5 days ago - Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes* - PRNewsWire
- 7 weeks ago - Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results - PRNewsWire
- 7 weeks ago - Elanco to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Elanco Announces Updates to Board of Directors - PRNewsWire
- 2 months ago - Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement - PRNewsWire
- 3 months ago - Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 3 months ago - Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis - PRNewsWire
- 4 months ago - Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs - PRNewsWire